<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3345255/" ref="ordinalpos=1114&amp;ncbi_uid=3996932&amp;link_uid=PMC3345255" image-link="/pmc/articles/PMC3345255/figure/fig1/" class="imagepopup">Figure 1.  From: MAPK/ERK <span class="highlight" style="background-color:">Signaling</span> in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions. </a></div><br /><div class="p4l_captionBody">MAPK/ERK signaling and the hallmarks of cancers. The MAPK/ERK pathway mediates several upstream signals from well-known oncogenic growth factors and proinflammatory stimulants. Activation of the MAPK/ERK pathway by growth factors, proinflammatory stimulants and gain-of-function mutations of Ras/Raf promotes phenotypic changes characteristic of cancer cells [9â€“14].</div></div>